Health Bulletin 3/April/2023

Here are the top health stories for the day:

No more rounds of NEET SS counselling 2022: MCC

In a major update, the Medical Counselling Committee (MCC) has announced that there will be no further rounds of NEET SS Counselling 2022.

Thus, all rounds of Super Speciality (DM/ MCh/ DNB SS) admissions for the academic session 2022-23 are over and the unallotted candidates will be getting their refund soon.

The notification issued to this effect by the MCC reads:

For more details, check out the link given below:

No More Rounds Of NEET SS Counselling 2022: MCC

US Health Body warns of deadly Marburg Virus after outbreak in Africa

CO2 embolism during laparoscopy procedure: Surgeon, Anaesthetist told to pay Rs 33 lakh compensation after patient death

Two doctors, a Surgeon and an Anesthetist have been ordered by the Gujarat State Consumer Dispute Redressal Commission to pay Rs 33.70 lakh compensation to the kin of a patient who died due to carbon dioxide embolism during a laparoscopy procedure, while the physician involved in the case was exonerated from the liability.

Presiding Member of the State Commission, R N Mehta observed that the two doctors were liable for not providing efficient services to the patient and that their action led to an irreversible condition of the patient and her death on the next day suggests that it was direct nexus with the cause of death of the patient.

For more details, check out the link given below:

CO2 Embolism During Laparoscopy Procedure: Surgeon, Anesthetist Told To Pay Rs 33 Lakh Compensation After Patient Death

New medicine found for treatment of heart failure, sleep apnea: Study

A new medicine is showing promise in treating heart failure, a common ailment linked to sleep apnea and a shorter lifespan.

The drug, known as AF-130, was tested in an animal model at Waipapa Taumata Rau, the University of Auckland where researchers found it improved the heart's ability to pump, but, equally important, prevented sleep apnoea, which itself reduces lifespan (see Nature Communications). "This drug does offer benefit for heart failure, but it's two for the price of one, in that it's also relieving the apnoea for which there is currently no drug, only CPAP (a breathing device), which is poorly tolerated," said Professor Julian Paton, director of the University's Manaaki Manawa, Centre for Heart Research.

For more health news, check out the Medical Dialogues official site:

https://medicaldialogues.in/